Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/259111 |
Resumo: | Dermatomycosis is a common fungal infection, and its treatment is limited by few antifungal agents. Clioquinol (CQ) is an antiparasitic agent that has been studied for new uses, such as antifungal and antiviral applications. CQ was incorporated into a lipid-based nanocarrier as a new, promising option for dermatomycosis. This study aimed to develop a CQ-loaded lipid-based nanocarrier for cutaneous application and to evaluate its antifungal activity. CQ-loaded nanoformulation (LBN-CQ) was developed using the ultrasonication method, and the particle size, polydispersity index (PDI), pH, zeta potential, and drug content were monitored for 45 days. To evaluate antifungal activity, broth microdilution and a time-kill assay were performed. LBN-CQ presented a particle size of 91 3 nm and PDI of 0.102 0.009. The zeta potential and pH values were 9.7 2.0 mV and 6.0 0.1, respectively. The drug content was 96.4 2.3%, and the encapsulation efficiency was 98.4%. LBN-CQ was able to reduce the minimum inhibitory concentration (MIC) in a 2-fold or 4-fold manner in most of the tested strains. Additionally, LBN-CQ presented stable fungistatic action that was not concentration- or time-dependent. In conclusion, the developed CQ-loaded nanocarrier is a promising treatment for skin fungal infections and a promising candidate for future randomized clinical trials. |
id |
UFRGS-2_46c0af4972984ce3848644c02d857071 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/259111 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Berlitz, Simone JacobusReginatto, PaulaMachado, Gabriella da Rosa MonteFuentefria, Alexandre MeneghelloMorisso, Fernando Dal PontContri, Renata VidorKülkamp-Guerreiro, Irene Clemes2023-06-17T03:37:32Z20231999-4923http://hdl.handle.net/10183/259111001163288Dermatomycosis is a common fungal infection, and its treatment is limited by few antifungal agents. Clioquinol (CQ) is an antiparasitic agent that has been studied for new uses, such as antifungal and antiviral applications. CQ was incorporated into a lipid-based nanocarrier as a new, promising option for dermatomycosis. This study aimed to develop a CQ-loaded lipid-based nanocarrier for cutaneous application and to evaluate its antifungal activity. CQ-loaded nanoformulation (LBN-CQ) was developed using the ultrasonication method, and the particle size, polydispersity index (PDI), pH, zeta potential, and drug content were monitored for 45 days. To evaluate antifungal activity, broth microdilution and a time-kill assay were performed. LBN-CQ presented a particle size of 91 3 nm and PDI of 0.102 0.009. The zeta potential and pH values were 9.7 2.0 mV and 6.0 0.1, respectively. The drug content was 96.4 2.3%, and the encapsulation efficiency was 98.4%. LBN-CQ was able to reduce the minimum inhibitory concentration (MIC) in a 2-fold or 4-fold manner in most of the tested strains. Additionally, LBN-CQ presented stable fungistatic action that was not concentration- or time-dependent. In conclusion, the developed CQ-loaded nanocarrier is a promising treatment for skin fungal infections and a promising candidate for future randomized clinical trials.application/pdfengPharmaceutics. Basel. Vol. 15, n. 2 (2023), 531, 14 p.DermatomicosesAntifúngicosNanotecnologiaClioquinolCutaneous diseasesClioquinolNanotechnologyAntifungalDermatomycosisDevelopment of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosisEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001163288.pdf.txt001163288.pdf.txtExtracted Texttext/plain52997http://www.lume.ufrgs.br/bitstream/10183/259111/2/001163288.pdf.txt0e5bfdcbeabc4cb125f514614678b28dMD52ORIGINAL001163288.pdfTexto completo (inglês)application/pdf2086237http://www.lume.ufrgs.br/bitstream/10183/259111/1/001163288.pdf375ada1509b998830e7183d0080458beMD5110183/2591112023-06-18 03:52:15.489309oai:www.lume.ufrgs.br:10183/259111Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-18T06:52:15Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis |
title |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis |
spellingShingle |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis Berlitz, Simone Jacobus Dermatomicoses Antifúngicos Nanotecnologia Clioquinol Cutaneous diseases Clioquinol Nanotechnology Antifungal Dermatomycosis |
title_short |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis |
title_full |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis |
title_fullStr |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis |
title_full_unstemmed |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis |
title_sort |
Development of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosis |
author |
Berlitz, Simone Jacobus |
author_facet |
Berlitz, Simone Jacobus Reginatto, Paula Machado, Gabriella da Rosa Monte Fuentefria, Alexandre Meneghello Morisso, Fernando Dal Pont Contri, Renata Vidor Külkamp-Guerreiro, Irene Clemes |
author_role |
author |
author2 |
Reginatto, Paula Machado, Gabriella da Rosa Monte Fuentefria, Alexandre Meneghello Morisso, Fernando Dal Pont Contri, Renata Vidor Külkamp-Guerreiro, Irene Clemes |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Berlitz, Simone Jacobus Reginatto, Paula Machado, Gabriella da Rosa Monte Fuentefria, Alexandre Meneghello Morisso, Fernando Dal Pont Contri, Renata Vidor Külkamp-Guerreiro, Irene Clemes |
dc.subject.por.fl_str_mv |
Dermatomicoses Antifúngicos Nanotecnologia Clioquinol |
topic |
Dermatomicoses Antifúngicos Nanotecnologia Clioquinol Cutaneous diseases Clioquinol Nanotechnology Antifungal Dermatomycosis |
dc.subject.eng.fl_str_mv |
Cutaneous diseases Clioquinol Nanotechnology Antifungal Dermatomycosis |
description |
Dermatomycosis is a common fungal infection, and its treatment is limited by few antifungal agents. Clioquinol (CQ) is an antiparasitic agent that has been studied for new uses, such as antifungal and antiviral applications. CQ was incorporated into a lipid-based nanocarrier as a new, promising option for dermatomycosis. This study aimed to develop a CQ-loaded lipid-based nanocarrier for cutaneous application and to evaluate its antifungal activity. CQ-loaded nanoformulation (LBN-CQ) was developed using the ultrasonication method, and the particle size, polydispersity index (PDI), pH, zeta potential, and drug content were monitored for 45 days. To evaluate antifungal activity, broth microdilution and a time-kill assay were performed. LBN-CQ presented a particle size of 91 3 nm and PDI of 0.102 0.009. The zeta potential and pH values were 9.7 2.0 mV and 6.0 0.1, respectively. The drug content was 96.4 2.3%, and the encapsulation efficiency was 98.4%. LBN-CQ was able to reduce the minimum inhibitory concentration (MIC) in a 2-fold or 4-fold manner in most of the tested strains. Additionally, LBN-CQ presented stable fungistatic action that was not concentration- or time-dependent. In conclusion, the developed CQ-loaded nanocarrier is a promising treatment for skin fungal infections and a promising candidate for future randomized clinical trials. |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-06-17T03:37:32Z |
dc.date.issued.fl_str_mv |
2023 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/259111 |
dc.identifier.issn.pt_BR.fl_str_mv |
1999-4923 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001163288 |
identifier_str_mv |
1999-4923 001163288 |
url |
http://hdl.handle.net/10183/259111 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Pharmaceutics. Basel. Vol. 15, n. 2 (2023), 531, 14 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/259111/2/001163288.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/259111/1/001163288.pdf |
bitstream.checksum.fl_str_mv |
0e5bfdcbeabc4cb125f514614678b28d 375ada1509b998830e7183d0080458be |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225089249705984 |